J&J sees itself as 'important player' in hepatitis C competition
This article was originally published in Scrip
Executive Summary
Compared with some of its rivals, Johnson & Johnson seems downright stealth about its approach to developing new treatments for hepatitis C, the liver-destroying virus that is believed to infect tens of millions of people around the world.